COMMUNIQUÉS West-GlobeNewswire

Santhera Announces Positive AIFA Board Decision on Reimbursement of AGAMREE® (vamorolone) in Italy
28/04/2026
Pratteln, Switzerland, April 28, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces that the Board of Directors of the Italian Medicines Agency, AIFA, has approved the reimbursement of AGAMREE® (vamorolone) for the [...]
Scancell receives FDA Fast Track Designation for iSCIB1+ in advanced melanoma and provides data update from its SCOPE Phase 2 study
28/04/2026
Potent and durable efficacy with iSCIB1+ of 77% progression free survival (PFS) at 20 months, in combination with ipilimumab and nivolumab, demonstrated in the Phase 2 SCOPE trial; more PFS and additional early overall [...]
Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase 3 trial
28/04/2026
Company announcement – No. 10 / 2026 Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in [...]
Boehringer Ingelheim’s novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase III trial
28/04/2026
In SYNCHRONIZE-1, participants lost up to an average of 39.2 lb (17.8 kg) from baseline after 76 weeks of treatment with survodutide, a glucagon/GLP-1 receptor dual agonist 1 The trial met both weight loss primary [...]
Bioxodes to present final Phase 2a trial results confirming breakthrough potential of BIOX-101 for intracerebral hemorrhage in poster at ESOC 2026
28/04/2026
Final results of BIRCH multicenter, randomized, open-label Phase 2a proof-of-concept BIRCH trial with 23 patients, conducted in Belgium Final results build on positive second interim results announced in September 2025 [...]
Castle Rock Hormone Health Announces National Franchise Launch with Franchise Sidekick Amid Growing Demand for Longevity Medicine
28/04/2026
Castle Rock Hormone Health launches a national franchise program with Franchise Sidekick, targeting 100–250 new clinics in 2026 to meet rising demand for longevity-focused, cash-pay hormone and preventive health [...]
Rapid Nutrition PLC Announces FY2025 Results and 2026 Strategic Outlook
28/04/2026
LONDON, April 27, 2026 (GLOBE NEWSWIRE) -- Rapid Nutrition PLC (Euronext Growth: ALRPD ), a global HealthTech company focused on evidence-based nutrition solutions, today announces its audited results for the financial [...]
New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation
28/04/2026
LA JOLLA, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875 [...]
Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach
28/04/2026
MELBOURNE, Australia and INDIANAPOLIS, April 28, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) announces an educational webinar exploring the evolution of PSMA 1 -targeted [...]
Tessera Therapeutics to Present New Preclinical Data Supporting In Vivo Program in Sickle Cell Disease and Advancements in In Vivo CAR-T Applications at the American Society of Gene and Cell Therapy 29th Annual Meeting
27/04/2026
SOMERVILLE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Tessera Therapeutics (“Tessera”), the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, today announced four presentations [...]
Rgenta Therapeutics Announces Two Oral Presentations Highlighting Proprietary RSwitch Technology at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting
27/04/2026
WOBURN, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for [...]
CVRx to Report First Quarter 2026 Financial and Operating Results and Host Conference Call on May 11, 2026
27/04/2026
MINNEAPOLIS, April 27, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions [...]
Asgard Therapeutics announces oral presentation at ASGCT 2026, showcasing advanced preclinical data on AT-108 – its first-in-class, off-the-shelf, gene-based cancer immunotherapy
27/04/2026
AT-108 induces powerful, personalized anti-cancer responses by forcing tumor cells to present their antigens to the immune system Data to be presented at ASGCT 2026 show when used as a monotherapy, AT-108 doubled median [...]
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting
27/04/2026
WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies [...]
Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer’s Disease
27/04/2026
- Late-breaking oral presentation: IV delivery of VY1706, a CNS penetrant AAV gene therapy for AD, demonstrates compelling pharmacology and safety in a 3-month GLP toxicology study in NHPs - - Additional data [...]
Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences
27/04/2026
CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that five [...]
Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting
27/04/2026
- Data underscore the differentiated capability of the clinically validated FORCE platform to cross the blood-brain barrier - WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a [...]
Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026
27/04/2026
WAYNE, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today [...]
Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting
27/04/2026
In vitro data demonstrated self-complementary AAV9 (scAAV9) enabled ~30-fold higher MeCP2 protein expression compared to single-stranded AAV9 (ssAAV9), supporting the ability to effectively deliver TSHA-102 to the CNS [...]

Pages